This is the first time an IL-23 blocking drug has been shown to improve signs and symptoms of psoriatic arthritis.
Treatments for Plaque Psoriasis
A new study advises selecting biologic therapies for psoriasis based on individual factors such as patients' comorbidities, preferences and clinical situation, as well as the advantages and disadvantages of particular biologic treatments.
Adalimumab may be effective for plaque psoriasis, but not heart disease and other inflammatory conditions associated with the condition. This study confirms that the inflammatory process is unique and that one treatment may not apply to other inflammatory conditions.
Belgian pharmaceutical firm UCB has entered the immunodermatology field in the U.S. market.
Efficacy and safety outcomes of clinical trials involving biologic psoriasis drugs overstate these drugs' real-world utility, shows a JAMA Dermatology study.
The TNF alpha inhibitor certolizumab pegol has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis, shows a study published in JAAD.
Brodalumab most cost-effective with high efficacy for plaque psoriasis, but IL-17 inhibitors as a whole outperform other biologics, study shows.
Twice-monthly certolizumab for plaque psoriasis could prove to be an option for patients who struggle with twice-weekly dosing, a study shows.
A study that compares the safety, efficacy and drug survival of biologics to biosimilars, finds that switching to a biosimilar had no significant impact on drug survival or safe
While there are biologics and systemic agents designed to control the severe form of plaque psoriasis, few treatments work as well in moderate plaque psoriasis. Apremilast may be a game changer.